Study S003263

Phase II Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Obese Nondiabetic Adult Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06886126
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 240
Start: 2025-02-07
Primary completion: 2025-09-23
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Obesity
Interventions: DRUG:HDM1005 injection or placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage Change From Baseline in Body Weight at Week 22 [Baseline, Week 22]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0039926	1034-OR: Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial XIAOYING LI, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06886126